Technical Analysis for VERU - Veru Inc.

Grade Last Price % Change Price Change
grade A 4.26 0.24% 0.01
VERU closed up 0.24 percent on Thursday, February 27, 2020, on approximately normal volume.

Trend Table & Recent Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Up Up Down
Historical VERU trend table...

Date Alert Name Type % Chg
20 DMA Support Bullish 0.00%
Wide Bands Range Expansion 0.24%
Down 3 Days in a Row Weakness 0.24%
Down 4 Days in a Row Weakness 0.24%
MACD Bearish Signal Line Cross Bearish 0.00%
Wide Bands Range Expansion 0.00%
Down 3 Days in a Row Weakness 0.00%
Stochastic Sell Signal Bearish -1.16%
Wide Bands Range Expansion -1.16%
Overbought Stochastic Strength -1.16%

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile

Veru Inc., a medical therapeutics company, develops, manufactures, and markets consumer health care products. The company’s pharmaceuticals product portfolio includes Tamsulosin delayed release sachet that is under bioequivalence study for the treatment of benign prostatic hyperplasia; MSS-722, a fixed ratio of trans- and cis-clomiphene citrate isomers, which is under the Phase II clinical trial to treat male infertility caused by testicular dysfunction; APP-944, a zuclomiphene citrate that is under the Phase II clinical trial for the treatment of hot flashes in men on prostate cancer hormonal therapies; and APP-111, an oral tubulin targeting chemotherapy, which is under the preclinical study to treat metastatic prostate, breast, and ovarian cancers, as well as APP-111/112 oral agents that target colchicine binding site of tubulin for the treatment of gout and familial mediterranean fever. It also provides consumer health and medical devices, including PREBOOST benzocaine wipes for premature ejaculation; and FC2, which is female disposable contraceptive device, as well as FC2 Female Condom for unintended pregnancy and sexually transmitted infections, including HIV/AIDS and the Zika virus. The company primarily serves global agencies, non-government organizations, ministries of health, and other governmental agencies directly, as well as through distribution agreements and other arrangements with commercial partners. It has operations in the United States, Brazil, Zimbabwe, South Africa, Angola, the Democratic Republic of the Congo, Tanzania, Malaysia, Spain, France, the United Kingdom, and internationally. The company was formerly known as The Female Health Company and changed its name to Veru Inc. in July 2017. Veru Inc. was founded in 1896 and is headquartered in Miami, Florida.
Chemistry Pharmaceuticals Chemical Compounds Organic Compounds Chemotherapy Prostate Cancer HIV/Aids Benign Prostatic Hyperplasia Infections Gout Consumer Health Care Products Ovarian Cancers Male Infertility Treatment Of Benign Prostatic Hyperplasia

Is VERU a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 4.74
52 Week Low 1.18
Average Volume 441,278
200-Day Moving Average 2.48
50-Day Moving Average 3.79
20-Day Moving Average 4.17
10-Day Moving Average 4.33
Average True Range 0.32
ADX 16.33
+DI 17.21
-DI 23.69
Chandelier Exit (Long, 3 ATRs ) 3.73
Chandelier Exit (Short, 3 ATRs ) 4.24
Upper Bollinger Band 4.73
Lower Bollinger Band 3.61
Percent B (%b) 0.58
BandWidth 26.85
MACD Line 0.17
MACD Signal Line 0.20
MACD Histogram -0.0317
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 4.77
Resistance 3 (R3) 4.77 4.59 4.69
Resistance 2 (R2) 4.59 4.46 4.60 4.66
Resistance 1 (R1) 4.43 4.38 4.51 4.43 4.63
Pivot Point 4.25 4.25 4.30 4.26 4.25
Support 1 (S1) 4.09 4.12 4.17 4.09 3.89
Support 2 (S2) 3.91 4.04 3.92 3.86
Support 3 (S3) 3.75 3.91 3.84
Support 4 (S4) 3.75